Buy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug Prospects

Fulcrum Therapeutics (FULC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 13. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on the stock and has a $16.00 price target.

Joseph Schwartz has given his Buy rating due to a combination of factors including the potential of Fulcrum Therapeutics’ clinical programs and a strategic partnership. Fulcrum Therapeutics, a biotechnology firm focused on developing treatments for rare diseases, has recently entered into a collaboration with Sanofi, which Schwartz views as an underappreciated but significant vote of confidence in Fulcrum’s lead drug candidate, losmapimod, for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The deal not only provides a validation of the drug’s potential but also involves a financial commitment that indicates serious due diligence from Sanofi, a factor that Schwartz believes should be positively impacting the stock value.
Furthermore, Schwartz sees Sanofi as an ideal partner that complements Fulcrum’s efforts with its neuromuscular expertise, proficiency with novel endpoints, and regulatory experience. The fact that losmapimod passed Sanofi’s stringent internal checks further solidifies its credibility. While investors have been more attuned to Fulcrum’s other clinical program, pociredir for sickle cell disease, Schwartz anticipates that the attention will shift towards losmapimod as it advances towards pivotal data release. The collaboration with Sanofi, the potential for increased market attention, and the validation of losmapimod’s prospects have led Schwartz to not only reiterate an Outperform rating but also to increase the price target for Fulcrum Therapeutics from $14 to $16.

In another report released on May 14, Oppenheimer also assigned a Buy rating to the stock with a $14.00 price target.

FULC’s price has also changed dramatically for the past six months – from $3.470 to $7.350, which is a 111.82% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Fulcrum Therapeutics (FULC) Company Description:

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.